// App-Quantinova.ai

78 : Reductions in absolute neutrophil count with sarilumab resulting in dose delays or dose decreases: effects on efficacy and safety

Researchers

Presenter

  • Jeffrey R Curtis

Principal Investigators

  • Gregory St John

  • Michael Pannucci

  • Yong Lin

  • Jos A Maldonado-Cocco

  • Thomas Huizinga

  • Marina Stanislav

  • Elaine Wilson

  • Paul Emery

Medical Centers

  • Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL

  • Medical Analytics, Medical Affairs, Regeneron Pharmaceuticals, Inc, Tarrytown, NY, USA

  • Medical Analytics, Medical Affairs, Regeneron Pharmaceuticals, Inc, Tarrytown, NY, USA

  • Clinical Science, Sanofi Genzyme, Bridgewater, NJ

  • Buenos Aires University School of Medicine, Universidad de Buenos Aires, Buenos Aires, ARGENTINA

  • Rheumatology, Leiden University Medical Centre, Leiden, NETHERLANDS

  • Rheumatology Research Institute, n. a. V.A. Nassonova, Moscow, RUSSIAN FEDERATION

  • Rheumatology, Sanofi Genzyme, Oxford, UNITED KINGDOM

  • Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK

Locations

  • United States

  • Argentina

  • Netherlands

  • Russia

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Blood/haematological Diseases

Disease

  • Neutropenia

Biomarkers

  • N/A

Drug/Treatment

  • Sarilumab

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • NA

Study Id's

  • NCT01061736

  • NCT01709578

  • NCT02332590

  • NCT01146652

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved